A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: The SEZE trial

Chinese Medical Journal

Volumn 125, Issue 19, 2012, Pages 3373-3381

  Chung, Woo Young ^a   Kang, Jeehoon ^b,c   Cho, Young Seok ^b   Park, Hae Jun ^b   Yang, Han Mo ^c   Seo, Jae Bin ^a   Suh, Jung Won ^b   Kim, Kwang Il ^a   Youn, Tae Jin ^b   Kim, Sang Hyun ^a   Chae, In Ho ^b   Zo, Joo Hee ^a   Kim, Myung A ^a   Choi, Dong Ju ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Late lumen loss; Sirolimus eluting stent; ST elevation myocardial infarction; Zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MORPHINE; NITRATE; RAPAMYCIN; ZOTAROLIMUS;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENOSIS; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 84867426794     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.19.003     Document Type: Article

References (52)

1. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
2. Zhang Q, Xu B, Yang YJ, Zhang RY, Li JP, Qiao SB, et al. Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result. A prospective, historically controlled, multi-center clinical study. Chin Med J 2007; 120: 533-538.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
4. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
6. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
7. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
8. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
9. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056-1061.
10. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784-2814.
11. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005; 112: 3876-3883.
12. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995-998.
13. Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bottcher M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009; 53: 658-664.
14. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
15. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
16. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
17. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166-170.
18. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236.
19. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006; 27: 988-993.
20. Hayward JA, Durrani AA, Shelton CJ, Lee DC, Chapman D. Biomembranes as models for polymer surfaces. III. Characterization of a phosphorylcholine surface covalently bound to glass. Biomaterials 1986; 7: 126-131.
21. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002; 23: 1697-1706.
22. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-345.
23. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005; 1: 157-164.
24. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010; 3: 1043-1050.
25. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447.
26. Xu B, Dou KF, Han YL, Lu SZ, Yang YJ, Huo Y, et al. A prospective multicenter parallel-controlled trial of Tivoli biodegradable-polymer-based sirolimus-eluting stent compared to Endeavor zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J 2011; 124: 811-816.
27. Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, et al. Impact of preinterventional arterial remodeling on in-stent neointimal hyperplasia and in-stent restenosis after coronary stent implantation. Circ J 2005; 69: 414-419.
28. Saito T, Date H, Taniguchi I, Nakamura S, Oka H, Mizuno Y, et al. Angiographic evaluation of culprit lesions in acute coronary syndrome: relation to the original site on previous coronary angiography. Jpn Circ J 1998; 62: 359-363.
29. Ojio S, Takatsu H, Tanaka T, Ueno K, Yokoya K, Matsubara T, et al. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000; 102: 2063-2069.
30. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, et al. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol 2002; 39: 274-280.
31. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation 1997; 96: 2183-2189.
32. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46: 1002-1005.
33. Pinto Slottow TL, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv 2007; 69: 1064-1074.
34. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 809-816.
35. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. New Engl J Med 2006; 355: 1105-1113.
36. Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, et al. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. Am J Cardiol 2007; 99: 1403-1408.
37. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Rationale and design of the examination trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention 2011; 7: 977-984.
38. Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. Chin Med J 2007; 120: 863-867.
39. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al. Comparison of zotarolimus-eluting stents with sirolimusand paclitaxel-eluting stents for coronary revascularization: The zest (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010; 56: 1187-1195.
40. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation 2006; 114: 798-806.
41. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The reality trial: a randomized controlled trial. JAMA 2006; 295: 895-904.
42. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
43. Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, et al. Volumetric intravascular ultrasound analysis of paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. Circulation 2009; 120: 1875-1882.
44. Mortier P, Van Loo D, De Beule M, Segers P, Taeymans Y, Verdonck P, et al. Comparison of drug-eluting stent cell size using micro-ct: important data for bifurcation stent selection. Euro Intervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2008; 4: 391-396.
45. Kim SW, Mintz GS, Ohlmann P, Hassani SE, Fernandez S, Lu L, et al. Frequency and severity of plaque prolapse within Cypher and Taxus stents as determined by sequential intravascular ultrasound analysis. Am J Cardiol 2006; 98: 1206-1211.
46. Kang WC, Ahn T, Lee K, Han SH, Shin EK, Jeong MH, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011; 7: 936-943.
47. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the Endeavor III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2011; 4: 543-550.
48. Kim HK, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, et al. Comparison of outcomes between zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2010; 105: 813-818.
49. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the Taxus-IV trial. J Am Coll Cardiol 2005; 45: 1193-1200.
50. Yao ZH, Matsubara T, Inada T, Suzuki Y, Suzuki T. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography. Chin Med J 2008; 121: 503-507.
51. Liu HL, Jin ZG, Luo JP, Ma DX, Yang SL, Liu Y, et al. Long-term effects of biodegradable versus durable polymer-coated sirolimus-eluting stents on coronary arterial wall morphology assessed by virtual histology intravascular ultrasound. Chin Med J 2011; 124: 836-844.
52. Park KW, Lim WH, Kim JH, Kang SH, Seo JW, Song YB, et al. Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. Int J Cardiol 2011; Epub ahead of print.